Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Alan Crane
AddedMar 31, 2024
UpdatedMay 31, 2026
Alan Crane

Alan Crane

CEO, XTuit Pharmaceuticals

Crunchbase

Alan Crane's Career

XTuit Pharmaceuticals
XTuit Pharmaceuticals

Waltham, MA, US

CEO· C-Suite · Management
Navitor Pharmaceuticals
Navitor Pharmaceuticals

Cambridge, MA, US

Board Member· Board
KSQ Therapeutics
KSQ Therapeutics

Cambridge, MA, US

Board Member· Board
Dyno Therapeutics
Dyno Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Alan Crane's Career

XTuit Pharmaceuticals
XTuit Pharmaceuticals
Series A$26M302011Waltham, MA, US
CEO· C-Suite · Management

Leadership at XTuit Pharmaceuticals

Rakesh K. JainRakesh K. JainFounder
Dave MottDave MottBoard Member

Similar to XTuit Pharmaceuticals

Novita PharmaceuticalsNovita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7
Xios TherapeuticsXios TherapeuticsBoston, MA, USTherapeuticsest. 2015Xios TherapeuticsBoston, MA, US · est. 2015

Xios Therapeutics: Innovating small molecule therapeutics for enhanced immuno-oncology treatments.

Pre-Seed · $7M30
XentriaXentriaChicago, IL, USBiopharmaceuticals, Therapeuticsest. 2020XentriaChicago, IL, US · est. 2020

Xentria: Innovating cost-effective bio-pharmaceutical solutions for rare diseases and oncological conditions.

Series B · $25M13
Thetis PharmaceuticalsThetis PharmaceuticalsRidgefield, CT, USDrug Developmentest. 2011Thetis PharmaceuticalsRidgefield, CT, US · est. 2011

Thetis Pharmaceuticals: Specializing in cardio-metabolic, cancer, and autoimmune disease treatments.

Series A · $22.9M30
Navitor Pharmaceuticals
Navitor Pharmaceuticals
Series B$98.2M362010Cambridge, MA, US
Board Member· Board

Leadership at Navitor Pharmaceuticals

Paul A. FriedmanPaul A. FriedmanBoard Member
Jean-François FormelaJean-François FormelaBoard Member
Thomas E HughesThomas E HughesBoard Member
Vinzenz PloererVinzenz PloererBoard Member
Marian NakadaMarian NakadaBoard Member
George P. VlasukGeorge P. VlasukBoard Member
KSQ Therapeutics
KSQ Therapeutics
Series C$156M852015Cambridge, MA, US
Board Member· Board

Leadership at KSQ Therapeutics

Mahesh KarandeMahesh KarandeBoard Member
David M. SabatiniDavid M. SabatiniFounder
George GolumbeskiGeorge GolumbeskiBoard Member
Frank StegmeierFrank StegmeierBoard Member
Pearl HuangPearl HuangBoard Member
Theo Melas-KyriaziTheo Melas-KyriaziBoard Member

Similar to KSQ Therapeutics

NKT TherapeuticsNKT TherapeuticsWaltham, MA, USTherapeuticsest. 2008NKT TherapeuticsWaltham, MA, US · est. 2008

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Celsius TherapeuticsCelsius TherapeuticsCambridge, MA, USTherapeuticsest. 2018Celsius TherapeuticsCambridge, MA, US · est. 2018

Celsius Therapeutics, a US-based biotech firm, develops drugs for cancer and autoimmune diseases.

Series B · $148M72
Quanta TherapeuticsQuanta TherapeuticsSan Francisco, CA, USCancer Therapeuticsest. 2018Quanta TherapeuticsSan Francisco, CA, US · est. 2018

Quanta, founded in 2018, is a San Francisco-based biotech firm specializing in novel cancer therapeutics.

Series D · $140.7M28
Dyno Therapeutics
Dyno Therapeutics
Series A$109M1332018Cambridge, MA, US
Board Member· Board

Leadership at Dyno Therapeutics

Nicole PaulkNicole PaulkBoard Member
Tomas BjorklundTomas BjorklundCo-Founder
George ChurchGeorge ChurchCo-Founder
Jorge CondeJorge CondeBoard Member
Eric KelsicEric KelsicCo-Founder
Adrian VeresAdrian VeresCo-Founder

Similar to Dyno Therapeutics

Apertura Gene TherapyApertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29
AavogenAavogenRockville, MD, USGene Therapeuticsest. 2015AavogenRockville, MD, US · est. 2015

US-based AAVogen, a biotech startup, innovates gene therapeutics for muscle wasting diseases.

Seed · $4.7M5
Affinia TherapeuticsAffinia TherapeuticsWaltham, MA, USGene Therapiesest. 2019Affinia TherapeuticsWaltham, MA, US · est. 2019

Affinia Therapeutics: A biotech firm innovating gene therapies for muscle and CNS diseases.

Series B · $170M75
Capsida BiotherapeuticsCapsida BiotherapeuticsBuena Park, CA, USGene Therapyest. 2019Capsida BiotherapeuticsBuena Park, CA, US · est. 2019

Capsida: A US-based biotech firm specializing in monogenetic and sporadic CNS/non-CNS disorders.

Late Stage Private · $140M132

Alan Crane's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Alan Crane

Luis ArbuluLuis ArbuluCo-Founder · XerticaOri AngelOri AngelCEO · XT Hi-TechRonald GoldRonald GoldBoard Member · NJ BioAlan AubreyAlan AubreyCEO · Top Technology VenturesPaul CastellaPaul CastellaBoard Member · Hera BiotechAndrew JanoffAndrew JanoffBoard Member · Taaneh